FDA Authorizes Nitenpyram for New World Screwworm
Silver Spring, Maryland, USA, September 3, 2026 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Animal & Veterinary – Food, Drugs & Medical Devices: Protecting Human and Animal Health.
Silver Spring, Maryland, USA, September 3, 2026 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use...
Ingelheim, Germany, and Bracknell, United Kingdom, September 1, 2026 Boehringer Ingelheim has launched SCOVELLA® (velagliflozin oral solution) in Great...
SILVER SPRING, MARYLAND, Aug 27, 2026 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization...
Silver Spring, Maryland, August 13, 2026 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization...
PARSIPPANY, N.J., August 13, 2026 Zoetis Inc. announced that the U.S. Food and Drug Administration has issued an Emergency...
Ingelheim, Germany, August,11, 2026 Boehringer Ingelheim has acquired Evax AG, a Swiss biotechnology company focused on equine health, expanding...
Johns Creek, Georgia, August, USA 10, 2026 Boehringer Ingelheim Animal Health is highlighting the next generation of veterinary researchers...
Indianapolis, Indiana, USA, August 8, 2026 Elanco Animal Health has received an Emergency Use Authorization (EUA) from the U.S....
SILVER SPRING, Md., July 15, 2026 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization...
BEVERLY, Mass., July 7, 2026 Akston Biosciences Corporation has announced encouraging preclinical data demonstrating that its investigational NGF-targeting Ambifect®...
